All articles by Urtė Fultinavičiūtė

Urtė Fultinavičiūtė

@ufulti

Urtė Fultinavičiūtė is a healthcare reporter for Clinical Trials Arena. Urtė's coverage focuses on clinical data management and clinical strategy. Urtė holds an MA in International Journalism from City, University of London.

2023 in review: Are clinical trial sponsors and regulators in sync?

The past year marked significant regulatory updates and changes across the globe, as regulators tried to keep up with the…
Diversity and ePROs: Still siloed concepts in the era of DCTs?

Decentralised clinical trials (DCTs) are often pinned as a silver bullet to increase a trial’s footprint and reach various populations…
Delpor on track with schizophrenia implant late-stage trials

Delpor is sketching out late-stage clinical trial plans for its drug-device combination implant DLP-114 (risperidone) in schizophrenia. After presenting topline…
Viriom outlines plans for upcoming infectious disease trials

Viriom plans to extend a Phase I trial investigating its influenza pill AV5124, according to chief science officer Dr David…
4Moving Biotech shares innovative trial plans for GLP-1 osteoarthritis drug

After recently completing the recruitment for its Phase I trial, 4Moving Biotech is already laying out plans for the upcoming…

BerGenBio to power ongoing NSCLC trial with synthetic control arm

BerGenBio plans to add a synthetic control arm to its ongoing Phase Ib/IIa trial investigating bemcentinib in non-small-cell lung cancer…
Profit vs inquiry: Clash of objectives in academic and commercial trials

Academic institutions and commercial entities play an important role in drug development and improving human health. While both types of…
Q&A: Pharma’s trial diversity goals may not answer health equity problems

Health is a fundamental human right, yet health inequity is one of the major problems across the world. Although the…
FT Summit: AI and regulatory changes at the forefront of industry’s mind

After a few years of disruption caused by the Covid-19 pandemic, it seems that the pharma and biotech industries can…
Health equity and trial diversity questions still not answered by pharma

While global players are more aware of health equity problems across the world, there are still lingering problems, according to…